velifer t1_ixw66p5 wrote
Reply to comment by fireisveryfun in A novel medication for hemophilia B has just been approved by the Food and Drug Administration. The treatment is a form of gene therapy, intended to replace a dysfunctional gene that leaves people unable to control their bleeding. by Sariel007
>It's a single dose,
That current evidence is showing will likely need to be re-administered every five years. That's not in their reports to the shareholders.
​
>manufactured in incredibly small amounts
They will make every single dose they can sell. This is not a supply issue. This is a patent and greed issue.
​
>From what I've gathered it looks like the price is intended to recoup research costs.
The price is set to maximize what an insurance company will pay. It's set a just slightly less than the price of clotting factors the patient will need if they don't use this therapy.
​
>That said, the burden to pay really should be covered or at the very least VERY heavily subsidized by the government.
The government already paid for it, much of the work was done with public dollars and grants.
Viewing a single comment thread. View all comments